“A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT” (2026) Journal of Multidisciplinary Sciences and Innovations, 5(03), pp. 1550–1553. doi:10.55640/.